NPs are also an important screening tool for HF in patients presenting with dyspnoea on cancer therapy, but it has been shown that a cut-off value of 100 ng/L for NT-proBNP has a high sensitivity (0.92), but low specificity (0.5) for cardiotoxicity as there are other causes of increased NPs including, for example atrial fibrillation and valvular heart disease [93]. Here, NPPB is linked to cancer.